University of California San Francisco
Give to UCSFUC San Francisco’s Thomas G. Martin, MD, a leading expert in blood cancers, has received a grant of nearly $4.6 million from the California Institute of Regenerative Medicine (CIRM) to produce a CAR T
Eric J. Small, MD, UCSF professor of Medicine and Urology Credit: UCSFThe American Society of Clinical Oncology (ASCO) has elected Eric J. Small, MD, FASCO, to serve as its president for the term
Researchers at UCSF and UC Berkeley are investigating the impact of pre- and post-natal exposures to tobacco smoke on the survival rate of children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Hematologists and oncologists from around the world will present new research and clinical findings at the American Society of Hematology’s (ASH) 65th Annual Meeting and Exposition. This year’s meeting will be held in San Diego from Dec. 8-12, 2023.
For 50 years, UCSF Benioff Hospital’s Comprehensive Sickle Cell Center has been serving patients with a mission “to improve clinical outcomes and quality of life for individuals living with sickle cell disease and their families across the lifespan.”
Two sisters are receiving a breakthrough, FDA-approved treatment for beta thalassemia at UCSF Benioff Children's Hospital, Oakland. This is the first real therapy other than monthly transfusions for a devastating disease that destines people to shorter lives.
UCSF Benioff Children’s Hospital Oakland is the first hospital in the West to administer a newly approved gene therapy to treat beta thalassemia with gene therapy, reducing the need for lifelong blood transfusions.
A new study shows that newborn screening for SCID is the only factor that actually boosts survival rates.
Oncology specialists from around the globe will gather for the American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest cancer therapies, technologies, research and education.
UCSF experts in multiple myeloma and other hematologic malignancies will attend the American Society of Hematology’s (ASH) 64th Annual Meeting and Exposition.
UCSF has revealed how blood vessel cells develop in the prenatal human brain, paving the way to fully understand the role of these cells in healthy brain development and disease.
A new national study led by UCSF found that more sophisticated devices that pair with smartphones don’t lead to better blood pressure control than home-use blood pressure cuffs.
The repercussions of overturning Roe v. Wade – and the failure of the Supreme Court to provide any guidance on exceptions related to the life and health of the mother – are potentially catastrophic for women who face a life-threating diagnosis of pregnancy associated cancers (PAC).
Blood tests taken within 24 hours of a traumatic brain injury (TBI) flag which patients are likely to die and which patients are likely to survive with severe disability, according to a study headed by UCSF, the University of Pennsylvania and the University of Michigan.
In a new study of long COVID, UCSF researchers identified biomarkers present at elevated levels that may persist for many months in the blood of study participants who had long COVID with neuropsychiatric symptoms.
UCSF’s Division of Hematology-Oncology is welcoming Krishna Komanduri, MD, as division chief of Hematology-Oncology at UCSF Health. Komanduri is an international leader in the fields of hematology-oncology, transplantation, and cellular immunotherapy. He will start at UCSF on July 1.
For years, physicians have been taught to prescribe different drugs to Black people with high blood pressure. A recent UCSF study calls that into question.
An anonymous $2 million gift will support Benioff Children's Hospital Oakland's growing sickle cell program.
The UCSF initiative aims to increase the effectiveness and availability of chimeric antigen receptor T-cell (CAR T) therapy for lymphoma patients.
UCSF Benioff Children’s Hospital Oakland has received the largest research trial grant in its history to launch an innovative clinical trial that aims to cure sickle cell disease.
UCSF is launching a new initiative to propel the development of living therapeutics – a category of treatments broadly defined as human and microbial living cells that are selected, modified, or engineered to treat or cure disease – and bring them quickly to patients.
Over the past four decades, UCSF has led the way in its heroic response to the AIDS epidemic, both locally and globally. This timeline covers some of the highlights at UCSF, in the nation and around the world after a mysterious disease affecting gay men was first reported on June 5, 1981.
Scientists at UC San Francisco, UC Berkeley and UCLA have received U.S. Food and Drug Administration approval to jointly launch an early phase, first-in-human clinical trial of a CRISPR gene correction therapy in patients with sickle cell disease using the patient’s own blood-forming stem cells.
A new research collaborative at UCSF will be focused on decoding the “rulebook” of metastatic cancer as a pathway to new treatments.
Administering stem cell or enzyme therapy in utero may be a path to alleviating some congenital diseases that often result in losing a pregnancy, according to a new study in mice by UCSF researchers. They showed that stem cells can enter the fetal brain during prenatal development and make up for cells that fail to make an essential protein.
UCSF Benioff Children’s Hospitals have successfully treated a months-old infant with a rare childhood leukemia using a targeted therapy approved for adults with inoperable liver cancer and advanced kidney cancer.
A Phase 3 study has found that patients with Sickle Cell Disease (SCD) who took a daily dose of the novel drug voxelotor had less anemia and made healthier red blood cells than patients receiving a placebo.